Clinical trial
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
NCT00211198 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00211198 |
|---|---|
| Title | Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) |
| Official title | Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Tufts Medical Center National Cancer Institute (NCI) NIH Ligand Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Cutaneous |
| Intervention type | Drug |
| Interventions | ONTAK (denileukin difitox, DAB389IL-2) |
| Enrollment | 60 |
| Start date | May 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 5, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: